Centazzo M, Manganaro L, Alvisi G
Viruses. 2023; 15(3).
PMID: 36992421
PMC: 10053624.
DOI: 10.3390/v15030712.
Curto P, Barro A, Almeida C, Vieira-Pires R, Simoes I
mBio. 2021; 12(6):e0305921.
PMID: 34872352
PMC: 8649778.
DOI: 10.1128/mBio.03059-21.
Sherry D, Worth R, Sayed Y
Adv Exp Med Biol. 2021; 1371:79-108.
PMID: 34351572
DOI: 10.1007/5584_2021_655.
La Monica G, Lauria A, Bono A, Martorana A
Int J Mol Sci. 2021; 22(11).
PMID: 34199858
PMC: 8200130.
DOI: 10.3390/ijms22116070.
Weber I, Wang Y, Harrison R
Viruses. 2021; 13(5).
PMID: 34066370
PMC: 8148205.
DOI: 10.3390/v13050839.
Structural Impacts of Drug-Resistance Mutations Appearing in HIV-2 Protease.
Laville P, Petitjean M, Regad L
Molecules. 2021; 26(3).
PMID: 33503916
PMC: 7865771.
DOI: 10.3390/molecules26030611.
Impacts of drug resistance mutations on the structural asymmetry of the HIV-2 protease.
Laville P, Fartek S, Cerisier N, Flatters D, Petitjean M, Regad L
BMC Mol Cell Biol. 2020; 21(1):46.
PMID: 32576133
PMC: 7310402.
DOI: 10.1186/s12860-020-00290-1.
Exploring the Reasons for Decrease in Binding Affinity of HIV-2 Against HIV-1 Protease Complex Using Interaction Entropy Under Polarized Force Field.
Cong Y, Li Y, Jin K, Zhong S, Zhang J, Li H
Front Chem. 2018; 6:380.
PMID: 30197882
PMC: 6117221.
DOI: 10.3389/fchem.2018.00380.
Exploration of the effect of sequence variations located inside the binding pocket of HIV-1 and HIV-2 proteases.
Triki D, Billot T, Visseaux B, Descamps D, Flatters D, Camproux A
Sci Rep. 2018; 8(1):5789.
PMID: 29636521
PMC: 5893546.
DOI: 10.1038/s41598-018-24124-5.
Inhibition Profiling of Retroviral Protease Inhibitors Using an HIV-2 Modular System.
Mahdi M, Szojka Z, Motyan J, Tozser J
Viruses. 2015; 7(12):6152-62.
PMID: 26633459
PMC: 4690855.
DOI: 10.3390/v7122931.
Four Amino Acid Changes in HIV-2 Protease Confer Class-Wide Sensitivity to Protease Inhibitors.
Raugi D, Smith R, Gottlieb G
J Virol. 2015; 90(2):1062-9.
PMID: 26559830
PMC: 4702657.
DOI: 10.1128/JVI.01772-15.
Structure of RC1339/APRc from Rickettsia conorii, a retropepsin-like aspartic protease.
Li M, Gustchina A, Cruz R, Simoes M, Curto P, Martinez J
Acta Crystallogr D Biol Crystallogr. 2015; 71(Pt 10):2109-18.
PMID: 26457434
PMC: 4601372.
DOI: 10.1107/S1399004715013905.
A Direct Interaction with RNA Dramatically Enhances the Catalytic Activity of the HIV-1 Protease In Vitro.
Potempa M, Nalivaika E, Ragland D, Lee S, Schiffer C, Swanstrom R
J Mol Biol. 2015; 427(14):2360-78.
PMID: 25986307
PMC: 4465046.
DOI: 10.1016/j.jmb.2015.05.007.
High-affinity RNA Aptamers Against the HIV-1 Protease Inhibit Both In Vitro Protease Activity and Late Events of Viral Replication.
Duclair S, Gautam A, Ellington A, Prasad V
Mol Ther Nucleic Acids. 2015; 4:e228.
PMID: 25689224
PMC: 4345311.
DOI: 10.1038/mtna.2015.1.
A modular system to evaluate the efficacy of protease inhibitors against HIV-2.
Mahdi M, Matuz K, Toth F, Tozser J
PLoS One. 2014; 9(11):e113221.
PMID: 25419967
PMC: 4242608.
DOI: 10.1371/journal.pone.0113221.
Revealing origin of decrease in potency of darunavir and amprenavir against HIV-2 relative to HIV-1 protease by molecular dynamics simulations.
Chen J, Liang Z, Wang W, Yi C, Zhang S, Zhang Q
Sci Rep. 2014; 4:6872.
PMID: 25362963
PMC: 4217091.
DOI: 10.1038/srep06872.
Human immunodeficiency virus-1 (HIV-1)-mediated apoptosis: new therapeutic targets.
Mbita Z, Hull R, Dlamini Z
Viruses. 2014; 6(8):3181-227.
PMID: 25196285
PMC: 4147692.
DOI: 10.3390/v6083181.
Critical differences in HIV-1 and HIV-2 protease specificity for clinical inhibitors.
Tie Y, Wang Y, Boross P, Chiu T, Ghosh A, Tozser J
Protein Sci. 2012; 21(3):339-50.
PMID: 22238126
PMC: 3375435.
DOI: 10.1002/pro.2019.
Targeting human immunodeficiency virus type 1 assembly, maturation and budding.
Wapling J, Srivastava S, Shehu-Xhilaga M, Tachedjian G
Drug Target Insights. 2011; 2:159-82.
PMID: 21901072
PMC: 3155237.
Revealing the dimer dissociation and existence of a folded monomer of the mature HIV-2 protease.
Louis J, Ishima R, Aniana A, Sayer J
Protein Sci. 2009; 18(12):2442-53.
PMID: 19798742
PMC: 2821264.
DOI: 10.1002/pro.261.